Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 Study): A randomized controlled trial

Chest

Volumn 144, Issue 3, 2013, Pages 952-958

  Tapson, Victor F ^a   Jing, Zhi Cheng ^c   Xu, Kai Feng ^d   Pan, Lei ^e   Feldman, Jeremy ^f   Kiely, David G ^g,h   Kotlyar, Eugene ⁱ   McSwain, C Shane ^b   Laliberte, Kevin ^b   Arneson, Carl ^b   Rubin, Lewis J ^j  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNITED THERAPEUTICS CORPORATION   (United States)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f Arizona Pulmonary Specialists Ltd   (United States)

^g SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j UCSD MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; TREPROSTINIL;

ADULT; AGED; ARTICLE; BORG DYSPNEA SCORE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; DYSPNEA FATIGUE INDEX; FATIGUE; FEMALE; FLUSHING; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HUMAN; JAW PAIN; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 84880766215     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2875     Document Type: Article

References (19)

1. McLaughlin VV, Archer SL, Badesch DB, et al ; American College of Cardiology Foundation Task Force on Expert Consensus Documents ; American Heart Association ; American College of Chest Physicians ; American Thoracic Society, Inc ; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 ; 53 (17): 1573-1619.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004 ; 351 (14): 1425-1436.
3. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002; 26(2): 194-201.
4. Whittle BJ, Silverstein AM, Mottola DM, Clapp LH. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 ; 84 (1): 68-75.
5. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004 ; 43 (12):S 13-S 24.
6. Simonneau G, Barst RJ, Galie N, et al ; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 ; 165 (6): 800-804.
7. Hiremath J, Thanikachalam S, Parikh K, et al; TRUST Study Group. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010 ; 29 (2): 137-149.
8. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010 ; 55 (18): 1915-1922.
9. Wade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol. 2004 ; 44 (1): 83-88.
10. White RJ, Allen R, Torres F, et al. Sustained plasma concentrations of treprostinil following chronic dosing of oral treprostinil in patients with pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med. 2009 ; 179 : A3360.
11. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012 ; 142 (6): 1383-1390.
12. Jing ZC, Parikh K, Pulido T, et al. Effi cacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013 ; 127 (5): 624-633.
13. Simonneau G, Rubin LJ, Galiè N, et al ; PACES Study Group. Addition of sildenafi l to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 ; 149 (8): 521-530.
14. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafi l and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002; 136(7): 515-522.
15. Galiè N, Olschewski H, Oudiz RJ, et al ; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Effi cacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, effi cacy (ARIES) study 1 and 2. Circulation. 2008; 117 (23): 3010-3019.
16. Galiè N, Ghofrani HA, Torbicki A, et al ; Sildenafi l Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafi l citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 ; 353 (20): 2148-2157.
17. Galiè N, Brundage BH, Ghofrani HA, et al ; Pulmonary Arterial Hypertension and Response to Tadalafi l (PHIRST) Study Group. Tadalafi l therapy for pulmonary arterial hypertension [published correction in Circulation. 2011;124(10):e279]. Circulation. 2009 ; 119 (22): 2894-2903.
18. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 ; 174 (11): 1257-1263.
19. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 ; 346 (12): 896-903.